Pasithea Therapeutics opened higher at $0.55, compared with its previous close of $0.53. In the last trading session, the stock traded between $0.50 and $0.55. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Pasithea Therapeutics is now worth
$ 1.11
Resulting in a loss of
$ 98.89 (98.89%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.01 (-2.44%)
Day High
$0.55
Day Low
$0.50
Day Open
$0.55
Prev Close
$0.53
Volume
1,96,845
1W Return
-0.38%
1M Return
15.08%
3M Return
8.58%
6M Return
-34.40%
1Y Return
-26.90%
Market Cap ($ Mn)
17
PE Ratio
-
PB Ratio
0.39
PEG Ratio
-
ROE
-92.55%
ROCE
-93.66%
EPS (TTM)
$-0.16
1 Week
-0.38%
1 Month
15.08%
3 Months
8.58%
6 Months
-34.40%
9 Months
-29.58%
Pasithea Therapeutics to present initial PAS-004 NF1 clinical data
Pasithea Therapeutics to present initial Phase 1/1b data for PAS-004. Oral session covers cutaneous neurofibromas; poster covers plexiform neurofibromas. Presentations scheduled for November 12–13, 2026, in Vienna. Marks first public disclosure of Part A trial results for adult NF1 patients.
1mo agoPasithea Therapeutics to present PAS-004 data at ESMO 2026
Pasithea Therapeutics Corp. will present Phase 1 data on PAS-004 at the ESMO Congress 2026 in Madrid. The poster session, scheduled for October 23, will cover the safety and pharmacokinetics of the macrocyclic MEK inhibitor. The company plans to release detailed results during the event.
3mo agoPasithea Therapeutics to attend B. Riley Securities summit
Pasithea Therapeutics Corp. announced its participation in the Mind, Muscle & Vision Summit on July 16, 2026, in Boston, hosted by B. Riley Securities. The company's management will conduct one-on-one meetings with investors. Pasithea is currently developing PAS-004, a macrocyclic MEK inhibitor, with ongoing clinical trials for advanced cancer and NF1.
4mo agoPasithea reports positive interim Phase 1 data for PAS-004
Pasithea Therapeutics reported positive interim Phase 1 data for PAS-004, showing long-term safety and durable clinical activity in advanced cancer patients. The study noted no dose-limiting toxicities and disease stabilization in a refractory population. The company amended the protocol to extend dose escalation and initiate a food effect study.
4mo agoHC Wainwright reiterates Buy on Pasithea Therapeutics
HC Wainwright & Co. analyst Sara Nik has reiterated a Buy rating for Pasithea Therapeutics, maintaining a price target of $3.
4mo agoPasithea expands NF1 trial with higher dose levels
Pasithea Therapeutics Corp. has amended the protocol for its Phase 1/1b trial of PAS-004 in NF1 patients, adding 24mg and 32mg dose levels and extending treatment duration to 18 months. The company has dosed 18 patients to date and remains on track for an interim data update in Q4 2026.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Pasithea Therapeutics is now worth
$ 1.11
Resulting in a loss of
$ 98.89 (98.89%)
Note: Past profits do not guarantee future returns.
